Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
, 35 (6), 991-6

Cytokine and Chemokine Profiles in Fibromyalgia, Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Potentially Useful Tool in Differential Diagnosis

Affiliations
Comparative Study

Cytokine and Chemokine Profiles in Fibromyalgia, Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Potentially Useful Tool in Differential Diagnosis

Daniel J Wallace et al. Rheumatol Int.

Abstract

Making a correct diagnosis is pivotal in the practice of clinical rheumatology. Occasionally, the consultation fails to provide desired clarity in making labeling an individual as having fibromyalgia (FM), systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). A chemokine and cytokine multiplex assay was developed and tested with the goal of improving and achieving an accurate differential diagnosis. 160 patients with FM, 98 with RA and 100 with SLE fulfilling accepted criteria were recruited and compared to 119 controls. Supernatant cytokine concentrations for IL-6, IL-8, MIP-1 alpha and MIP-1 beta were determined using the Luminex multiplex immunoassay bead array technology after mitogenic stimulation of cultured peripheral blood mononuclear cells. Each patient's profile was scored using a logistical regression model to achieve statistically determined weighting for each chemokine and cytokine. Among the 477 patients evaluated, the mean scores for FM (1.7 ± 1.2; 1.52-1.89), controls (-3.56 ± 5.7; -4.59 to -2.54), RA (-0.68 ± 2.26; -1.12 to -0.23) and SLE (-1.45 ± 3.34, -2.1 to -0.79). Ninety-three percent with FM scored positive compared to only 11% of healthy controls, 69% RA or 71% SLE patients had negative scores. The sensitivity, specificity, positive predictive and negative predictive value for having FM compared to controls was 93, 89, 92 and 91%, respectively (p < 2.2 × 10(-16)). Evaluating cytokine and chemokine profiles in stimulated cells reveals patterns that are uniquely present in patients with FM. This assay can be a useful tool in assisting clinicians in differentiating systemic inflammatory autoimmune processes from FM and its related syndromes and healthy individuals.

Figures

Fig. 1
Fig. 1
Receiver operating characteristic (ROC) curve for CCC test scores of 160 FM patients and 119 controls. The area under the curve (AUC) is 0.96
Fig. 2
Fig. 2
The probability densities of CCC test scores of 119 controls, 160 FM patients, 100 SLE patients and 98 RA patients

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles

References

    1. Wallace DJ, Schwartz E, Chi-Lin H, Peter JB. The ‘rule out lupus’ rheumatology consultation: clinical outcomes and perspectives. J Clin Rheumatol. 1995;1(3):158–164. doi: 10.1097/00124743-199506000-00005. - DOI - PubMed
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia, report of the multicenter criteria committee. Arthritis Rheum. 1990;33:160–172. doi: 10.1002/art.1780330203. - DOI - PubMed
    1. Clauw DJ, Fibromyalgia A. Clinical review. JAMA. 2014;311:1547–1555. doi: 10.1001/jama.2014.3266. - DOI - PubMed
    1. Chandran A, Schaefer C, Ryan K, Baik R, Mc Nett M, Zlateva G. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age US adults. J Manag Care Pharm. 2012;18:415–426. - PubMed
    1. Curtis JR, n Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012;64:1794–1803. doi: 10.1002/acr.21767. - DOI - PMC - PubMed

Publication types

MeSH terms

Feedback